; The Flow Cytometry Shared Service (FCSS) at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) offers flow cytometry equipment and technical expertise to UMGCC members conducting research in cancer biology and other areas of basic and applied science. Services are open to the entire University of Maryland campus, but UMGCC accounts for about 75 percent of the total use. FCSS provides full scale, state-of-the-art flow cytometry services, from functional and phenotypic analysis to cell sorting. Analytical instruments include a modern, fully digital, 3-laser Becton Dickinson (BD) LSR II flow cytometer, and two analog flow cytometers: a BD LSR 1 and a BD FACScan instrument. Cell sorting is conducted with (1) a BD FACSAria I digital instrument equipped with two lasers and seven-colordetection capability and (2) a BD FACSVantage SE instrument upgraded with BD's Digital Acquisition System (DIVA) and equipped with three lasers including a tunable krypton laser for 351 nm ultraviolet excitation. FCSS also offers users both operator-assisted and self-service data analysis on several platforms as well as experimental training and consultation to support project design for individual analytical or sorting experiments. The effectiveness of FCSS is evident from the steady increase of its utilization in recent years, the more than 50 principal investigators who are using the shared service, and the number of publications and National Cancer Institute-funded projects supported by experiments conducted with the help ofthe shared service. The goal of FCSS is to further increase the breadth and scope of its services by expanding cell-sorting capabilities;supporting novel, flow cytometry-based analytical applications;and strengthening cooperation with other UMGCC shared sen/ices to help introduce innovative, cutting-edge technologies to UMGCC investigators.
State-of-the-art fluorescent cell sorting and analytical flow-cytometry capabilities are indispensable to enhance our understanding of basic disease processes, ranging from stem cell biology to viral infections to cancer. The scientific objective of this facility is to provide flow cytometry services for investigators, in the Program in Oncology and campuswide, to assist them in achieving their scientific research goals.
|Wang, Junxiang; Zhao, Liang; Ye, Yanfang et al. (2018) Adverse event detection by integrating twitter data and VAERS. J Biomed Semantics 9:19|
|Furusawa, Aki; Reiser, John; Sadashivaiah, Kavitha et al. (2018) Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41:53-63|
|Nathenson, Michael J; Conley, Anthony P; Sausville, Edward (2018) Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23:71-83|
|Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Exploring the effect of library preparation on RNA sequencing experiments. Genomics :|
|Nathenson, Michael J; Barysauskas, Constance M; Nathenson, Robert A et al. (2018) Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 16:203|
|Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546|
|Kerr, Candace; Adhikary, Gautam; Grun, Daniel et al. (2018) Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma. Mol Carcinog 57:3-11|
|Connolly, Sean; Quasi-Woode, Devona; Waldron, Laura et al. (2018) Calcineurin Regulatory Subunit Calcium-Binding Domains Differentially Contribute to Calcineurin Signaling in Saccharomyces cerevisiae. Genetics 209:801-813|
|Pauza, C David; Liou, Mei-Ling; Lahusen, Tyler et al. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Front Immunol 9:1305|
|Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Res 78:4411-4423|
Showing the most recent 10 out of 257 publications